Tharimmune (THAR) News Today $5.95 -0.10 (-1.65%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.85 -0.10 (-1.66%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Biotech Stocks To Watch Today - August 25thAugust 28 at 3:41 AM | americanbankingnews.comTharimmune (THUR) Tumbles 20.7% on $5-Million Share SaleAugust 27 at 12:11 PM | insidermonkey.comTharimmune files to sell 2.46M shares of common stock for holdersAugust 26, 2025 | msn.comTharimmune Inc trading halted, volatility trading pauseAugust 26, 2025 | msn.comTharimmune Shares Drop After Securities Purchase AgreementAugust 26, 2025 | marketwatch.comWhy Tharimmune (THAR) Stock Exploded This WeekAugust 23, 2025 | msn.comWhy Is Tharimmune Stock (THAR) Blowing Up?August 22, 2025 | msn.comTharimmune reports pharmacokinetic simulation results for TH104August 20, 2025 | msn.comTharimmune secures key global patents for TH-104August 13, 2025 | msn.comTharimmune Completes Private Placement AgreementAugust 1, 2025 | msn.comMonday’s Insider Moves: Top Buys and Sells in US StocksJune 24, 2025 | investing.comTharimmune, Inc. (NASDAQ:THAR) CEO Sireesh Appajosyula Acquires 61,496 SharesJune 24, 2025 | insidertrades.comTharimmune CFO Don Kim ResignsJune 17, 2025 | marketwatch.comTharimmune announces executive changes and new agreementsJune 13, 2025 | investing.comTharimmune advances opioid prophylaxis drug TH104May 7, 2025 | investing.comTharimmune announces board retirements ahead of annual meetingApril 26, 2025 | investing.comTharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | finanznachrichten.deTharimmune announces preclinical data from expanded pipeline with HS1940April 9, 2025 | markets.businessinsider.comTharimmune receives Nasdaq non-compliance noticeApril 6, 2025 | investing.comTharimmune announces FDA feedback on NDA path for TH104April 1, 2025 | markets.businessinsider.comTharimmune announces FDA feedback on TH104 NDA pathApril 1, 2025 | markets.businessinsider.comTharimmune announce preclinical TH023 resultsMarch 25, 2025 | markets.businessinsider.comTharimmune appoints new CFO following resignationMarch 1, 2025 | investing.comRodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy RecommendationDecember 7, 2024 | msn.comTharimmune presents clinical data on TH104 for chronic pruritusNovember 19, 2024 | markets.businessinsider.comWhat's Going On With Tharimmune Shares Monday?November 18, 2024 | benzinga.comTharimmune, Inc. (NASDAQ:THAR) COO Purchases $10,100.00 in StockNovember 14, 2024 | insidertrades.comTharimmune granted patent for delivery of molecularly targeted therapeuticsNovember 13, 2024 | markets.businessinsider.comTharimmune Inc.: Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted TherapeuticsNovember 13, 2024 | finanznachrichten.deTharimmune receives regulatory feedback from EMA for TH104 programOctober 31, 2024 | markets.businessinsider.comWhat's Going On With Tharimmune Shares Wednesday?October 31, 2024 | msn.comTharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific MeetingOctober 28, 2024 | markets.businessinsider.comTharimmune (NASDAQ:THAR) Stock Quotes, Forecast and News SummaryOctober 1, 2024 | benzinga.comTHAR Stock Earnings: Tharimmune Reported Results for Q2 2024August 12, 2024 | investorplace.comTharimmune, Inc.: Tharimmune to Present at 2024 BIO International ConventionMay 29, 2024 | finanznachrichten.deTharimmune to Present at 2024 BIO International ConventionMay 29, 2024 | finance.yahoo.comShort Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 83.2%May 28, 2024 | marketbeat.comWhy Is Tharimmune (THAR) Stock Moving Today?May 24, 2024 | investorplace.comWhy Tharimmune (THAR) Shares Are MovingMay 22, 2024 | msn.comTharimmune, Inc.: Tharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | finanznachrichten.deTharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | finance.yahoo.comTHAR Stock Earnings: Tharimmune Reported Results for Q4 2023May 9, 2024 | investorplace.comStonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus ManagementMay 2, 2024 | finance.yahoo.comTharimmune, Inc. (THAR)April 24, 2024 | finance.yahoo.comTharimmune Inc THARApril 17, 2024 | morningstar.comMHill & Smith PLC HILSApril 17, 2024 | morningstar.comMTharimmune forms advisory board to guide drug developmentApril 16, 2024 | investing.comTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialFebruary 21, 2024 | msn.comTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver DiseaseFebruary 20, 2024 | msn.comTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finanznachrichten.de Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. THAR Media Mentions By Week THAR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THAR News Sentiment▼0.241.05▲Average Medical News Sentiment THAR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THAR Articles This Week▼100▲THAR Articles Average Week Get the Latest News and Ratings for THAR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Tharimmune and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Celularity News Today Oramed Pharmaceuticals News Today CEL-SCI News Today Ovid Therapeutics News Today Entera Bio News Today CervoMed News Today Atara Biotherapeutics News Today Vaxart News Today OKYO Pharma News Today Pyxis Oncology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THAR) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THAR Stock Alerts